论文部分内容阅读
本文论述了1975年中临床研究最多的化合物和新报道的有抗肿瘤活性的化合物。烷化剂和亚硝脲类氯代乙胺化合物和有关的烷化剂,仍然是治疗肿瘤最广泛使用的一类化合物。几乎所有新的辅助化疗方案中,至少用一个周期的环磷酰胺或BCNU,CCNU,MeCCNU,或最近研究的水溶性亚硝脲ACNU。ACNU在体内的性质类似于脂溶性亚硝脲化合物,并发现它在诱导治疗小细胞肺癌和转移性肺癌有良好作用。氯乙氨苯肽(Peptichemio,PTC,l)是六种m-L-苯丙氨酸氮芥多肽混合物。由于它具有肽基因,故认为有抗代谢作用,此药以1～1.5mg/kg/天的剂量,连续3～5天静脉给药几个疗程的方案,已用于各种实体瘤治疗的诱导期。用同样的治疗方案,对晚期儿童神经母细胞瘤,12例
This article discusses the most clinically studied compounds in mid-1975 and newly reported compounds with antitumor activity. Alkylating agents and nitrosourea chloroethylamine compounds and related alkylating agents are still the most widely used class of compounds in the treatment of tumors. In almost all new adjuvant chemotherapy regimens, at least one cycle of cyclophosphamide or BCNU, CCNU, MeCCNU, or the most recently studied water-soluble nitrosourea ACNU. ACNU is similar in vivo to a fat-soluble nitrosourea compound and found to have a good effect in inducing the treatment of small cell lung cancer and metastatic lung cancer. Peptichemio (PTC, l) is a mixture of six m-L-phenylalanine mustard polypeptides. Because it has a peptide gene, it is considered anti-metabolic effect, the drug dose of 1 ~ 1.5mg / kg / day for 3 to 5 days for several courses of intravenous administration of a program has been used for the treatment of various solid tumors Induction period. With the same treatment, for advanced neuroblastoma in children, 12 cases